Search

Displaying results 2511 - 2520 of 2674 in total
  1. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [L42245] In January 2023, the FDA granted accelerated approval to intravenous mosunetuzumab based on response rate.

  2. Target

    Neutral amino acid transporter B(0)

    go.drugbank.com/bio_entities/BE0000236
    TargetTransporterHumans

    Mediates D-serine release from the retinal glia potentially affecting NMDA receptor function in retinal neurons.

    Synonyms: Baboon M7 virus receptor, RD114/simian type D retrovirus receptor
  3. Target

    CD320 antigen

    go.drugbank.com/bio_entities/BE0019797
    TransporterHumans

    Receptor for transcobalamin saturated with cobalamin (TCbl) (PubMed:18779389). Plays an important role in cobalamin uptake (PubMed:18779389, PubMed:20524213).

    Synonyms: Transcobalamin receptor
  4. Target

    Volume-regulated anion channel subunit LRRC8A

    go.drugbank.com/bio_entities/BE0016599
    TargetHumans

    Essential component of the volume-regulated anion channel (VRAC, also named VSOAC channel), an anion channel required to maintain a constant cell volume in response to extracellular or intracellular osmotic changes (PubMed:24725410, PubM...

    Synonyms: Leucine-rich repeat-containing protein 8A
  5. Target

    Steroidogenic factor 1

    go.drugbank.com/bio_entities/BE0003359
    TargetHumans

    Transcriptional activator. Essential for sexual differentiation and formation of the primary steroidogenic tissues (PubMed:27378692). Binds to the Ad4 site found in the promoter region of steroidogenic P450 genes such as CYP11A, CYP11B a...

    Synonyms: Steroid hormone receptor Ad4BP, Nuclear receptor subfamily 5 group A member 1
  6. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors.

  7. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    [L64061] The FDA granted vusolimogene oderparepvec-wtpg accelerated approval on August 6, 2026, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed

  8. Drug

    Tegaserod

    go.drugbank.com/drugs/DB01079
    ApprovedWithdrawn

    Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C).

    Categories: Serotonin-4 Receptor Agonist, Serotonin 4 Receptor Agonists
  9. Drug

    Tepotinib

    go.drugbank.com/drugs/DB15133
    ApprovedInvestigational

    Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February

  10. Drug

    Dronedarone

    go.drugbank.com/drugs/DB04855
    ApprovedInvestigational

    [T28] Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009.

    Categories: Adrenergic alpha-1 Receptor Antagonists